Radiosynthesis of 18F-(R8,15,21, L17)-vasoactive intestinal peptide and preliminary evaluation in mice bearing C26 colorectal tumours

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nuclear medicine communications

• Publication date

  2007-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/MNM.0b013e328155d111PMID 17460542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiolabeling and in vitro and in vivo Characterization of [18F]FB‐[R8,15,21, L17]‐VIP as a PET Imaging Agent for Tumor Overexpressed VIP Receptors

  2006cited by this paper
• Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death.

  2004cited by this paper
• 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.

  2004cited by this paper
• Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences.

  2004cited by this paper
• Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases

  2004cited by this paper
• Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.

  2004cited by this paper
• Radiolabelling of isopeptide N epsilon-(gamma-glutamyl)-L-lysine by conjugation with N-succinimidyl-4-[18F]fluorobenzoate.

  2003cited by this paper
• Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET.

  2003cited by this paper
• Radiolabelling of isopeptide Nε-(γ-glutamyl)-l-lysine by conjugation with N-succinimidyl-4-[18F]fluorobenzoate

  2003cited by this paper
• A complete substitutional analysis of VIP for better tumor imaging properties

  2002cited by this paper
• VPAC receptors for VIP and PACAP.

  2002cited by this paper
• Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts.

  2002cited by this paper
• Recent progress in fluorine-18 labelled peptide radiopharmaceuticals

  2001cited by this paper
• Challenges and controversies in immunization safety.

  2001cited by this paper
• Recent progress in fluorine-18 labelled peptide radiopharmaceuticals

  2001cited by this paper
• 99mTc labeled VIP analog: evaluation for imaging colorectal cancer.

  2001cited by this paper
• 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans.

  2000cited by this paper
• [123I]VIP receptor scintigraphy in patients with pancreatic adenocarcinomas

  2000cited by this paper
• Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours

  2000cited by this paper
• 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies.

  1999cited by this paper
• (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors.

  1998cited by this paper
• Evaluation of human transferrin radiolabeled with N-succinimidyl 4-[fluorine-18](fluoromethyl) benzoate.

  1996cited by this paper
• 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract.

  1996cited by this paper
• A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation.

  1996cited by this paper
• In Vitro Identification of VIP Receptors in Human Tumors: Potential Clinical Implications

  1996cited by this paper
• Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.

  1995cited by this paper
• Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma

  1995cited by this paper
• Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.

  1994cited by this paper
• One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling.

  1994cited by this paper
• Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret.

  1989cited by this paper
• Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects.

  1978cited by this paper
• Polypeptide with Broad Biological Activity: Isolation from Small Intestine

  1970cited by this paper

• Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

  2016cites this paper
• Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review).

  2014cites this paper
• Advances in Radiotracer Development for Molecular Imaging

  2014cites this paper
• Molecular imaging of cancer with radiolabeled peptides and PET.

  2012cites this paper
• Radiometal targeted tumor diagnosis and therapy with peptide hormones.

  2008cites this paper